Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00145925 | Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes | PHASE3 | COMPLETED | 11,140 | — | — | Jun 1, 2001 | Mar 1, 2008 | Apr 11, 2025 | 5 | Australia, Canada +3 |
| Arm | Type | Description |
|---|---|---|
| Blood pressure | PLACEBO_COMPARATOR | Perindopril indapamide vs placebo |
| Glucose control | OTHER | Standard versus intensive glucose control |
| Name | Type | Description |
|---|---|---|
| Perindopril-indapamide | DRUG | - |
| Gliclazide MR-based glucose lowering | DRUG | - |
Inclusion Criteria: 1. A diagnosis of type 2 diabetes mellitus first made at age 30 years or older 2. Age 55 years or older at entry 3. Ability to provide informed consent 4. A substantially elevated risk of cardiovascular disease, indicated by: * A history of major macrovascular disease define...